Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody designed to selectively bind to the B cell maturation antigen (BCMA) on the surface of multiple myeloma (MM) cells and the CD3 receptor on T cells. This dual binding facilitates the targeted destruction of MM cells by directing and activating T cells to recognize and eliminate BCMA-expressing tumor cells. Linvoseltamab is primarily utilized in research focused on relapsed or refractory multiple myeloma (RRMM), providing a valuable tool for investigating novel therapeutic strategies in this challenging clinical area.
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody designed to selectively bind to the B cell maturation antigen (BCMA) on the surface of multiple myeloma (MM) cells and the CD3 receptor on T cells. This dual binding facilitates the targeted destruction of MM cells by directing and activating T cells to recognize and eliminate BCMA-expressing tumor cells. Linvoseltamab is primarily utilized in research focused on relapsed or refractory multiple myeloma (RRMM), providing a valuable tool for investigating novel therapeutic strategies in this challenging clinical area.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
